Columbia University’s Vor Biopharma has collected more capital from shareholders including Osage University Partners, Johnson & Johnson and PureTech Health.

Vor Biopharma, a US-based cancer treatment developer spun out of Columbia University, yesterday raised $110m in a series B round featuring spinout-focused investment firm Osage University Partners (OUP).
RA Capital Management led the round, which also included healthcare group Johnson & Johnson, pharmaceutical companies PureTech Health, life science real estate investment trust Alexandria Real Estate Equities and financial services group Fidelity.
Pagliuca Family Office and 5AM Ventures filled out the round together with undisclosed backers. Johnson & Johnson and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in